about
Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center.Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer.Treatment of bicalutamide-induced gynecomastia with breast-reduction surgery in prostate cancer.Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer.SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancerNeoadjuvant and adjuvant chemotherapy for high-risk localized prostate cancer.Chemotherapy for high-risk localized prostate cancer.The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid.Association of prostate cancer risk Loci with disease aggressiveness and prostate cancer-specific mortality.The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP).Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer.The impact of statin use on the efficacy of abiraterone acetate in patients with castration-resistant prostate cancer.Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer.Association of SLCO2B1 Genotypes With Time to Progression and Overall Survival in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer.A Genetic Variation of SOD2 Does Not Determine Duration of Response to Androgen Deprivation Therapy for Prostate CancerActivity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer.Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone.Elevated insulin-like growth factor binding protein-1 (IGFBP-1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival.Phase II trial of RAD001 and bicalutamide for castration-resistant prostate cancer.Reply to clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease.Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer.Patients with Biopsy Gleason 9 and 10 Prostate Cancer Have Significantly Worse Outcomes Compared to Patients with Gleason 8 Disease.Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer.Association of HSD3B1 Genotype With Response to Androgen-Deprivation Therapy for Biochemical Recurrence After Radiotherapy for Localized Prostate Cancer.Clinical predictors of survival in men with castration-resistant prostate cancer: evidence that Gleason score 6 cancer can evolve to lethal disease.Long-term Follow-up of a Phase II Trial of Chemotherapy Plus Hormone Therapy for Biochemical Relapse After Definitive Local Therapy for Prostate CancerResponse to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancerTreatment of a radiation-induced rectal ulcer with hyperbaric oxygen therapy in a man with prostate cancer
P50
Q31037387-24B625E6-2BDF-483A-917C-9200DA552EB8Q33667666-E37A39E5-D830-4C0C-9FA3-AC0AA9901BFBQ34539610-7D5D41C3-88D7-48E9-9CD6-5F6EFA971339Q34751456-8554219D-D126-4571-AFA1-61E95CD24054Q35112055-07F0D5E9-178A-4AFA-8BFE-9C14FD5C1163Q35876397-1542102B-B297-4AD8-838B-2F26566C3BD8Q36421099-5B7447EE-517E-4A18-AC54-6D51CD25A63FQ36740442-1A9EE0C0-1DD6-49E0-9929-6F4D400B2EE5Q37262639-AD9E0AF5-70A1-44BB-B124-03C7E0471CD4Q38593365-52383436-3A5B-4785-9A6B-036A9C118A47Q38852322-23C04887-288F-4655-9A6C-5E0B5A813B3FQ40099945-3B5FE686-1B0F-46E1-B63A-AAF5E7573FF3Q40395168-8914EB76-7317-4360-BF31-3BE42ABA43D0Q42019892-09CBC11C-2DA0-4763-8ECC-37BDC71EA2BEQ42260354-392A15A3-C481-49BA-9ADD-D51BA2915C5CQ43253423-D0868A26-D1B8-4382-AC68-285858B59F82Q43264893-EE7911F4-1A9B-4345-9FD5-33C3B4E13BD1Q43629106-38364C2D-5D95-4487-93F9-38975F116509Q45850976-AFC583E8-6BC3-4681-89B2-DD73C5462B03Q46246619-17373038-609D-43F0-A08C-967ACF40304AQ46694969-11567235-F6FB-465D-9961-E47E40376733Q46735412-EAE5D035-123C-44A5-8D64-2AC823830ED2Q46816117-BD14BAD2-0DAD-4667-85E4-29BEF2528D53Q47239084-CE56A72C-9C70-4CC6-A8DD-C600FD7B54B3Q50951455-7DA44665-60C9-4FD0-B1B2-484254882554Q57193371-9F47ED16-E7E0-4D73-8195-F6ECF8A49D2FQ60156307-6317D1CA-0197-4B4B-A6BA-C759C682D712Q79396497-B97DFFEF-8DAB-4624-844F-E82A5437617B
P50
name
Mari Nakabayashi
@en
Mari Nakabayashi
@nl
type
label
Mari Nakabayashi
@en
Mari Nakabayashi
@nl
prefLabel
Mari Nakabayashi
@en
Mari Nakabayashi
@nl